2026-04-14T04:25:21Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/118582025-10-24T10:16:58Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc DE HARO DEL MORAL, F JAVIER author Aguade Bruix, Santiago author Tabuenca Mateo, Maria Josefa author TAMAYO ALONSO, M. PILAR author Mohamed-Salem, Laroussi author Bernal, Laura author 2024-08-22T10:22:48Z 2024-08-22T10:22:48Z 2024-05-29 Bone scintigraphy; Cardiac amyloidosis; Incidental cardiac uptake Gammagrafia òssia; Amiloïdosi cardíaca; Captació cardíaca incidental Gammagrafía ósea; Amiloidosis cardíaca; Captación cardíaca incidental Aim Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy. Methods and results This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with >50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1–15.7). All were >70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (p < 0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p = 0.025). Conclusions This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients. This study was sponsored by Pfizer SLU. Pfizer contributed to the design of the project and writing of the manuscript under the supervision of the rest of the authors. http://hdl.handle.net/11351/11858 Neuropatia Miocardi - Malalties Gammagrafia Ossos - Imatgeria DISEASES::Nervous System Diseases::Neurodegenerative Diseases::Heredodegenerative Disorders, Nervous System::Amyloid Neuropathies, Familial Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging DISEASES::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Radionuclide Imaging ENFERMEDADES::enfermedades del sistema nervioso::enfermedades neurodegenerativas::trastornos heredodegenerativos del sistema nervioso::neuropatías amiloideas familiares Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::imagen radioisotópica Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study